UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
11.77
+0.32 (2.79%)
Nov 21, 2024, 1:38 PM EST - Market open
UroGen Pharma Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for UroGen Pharma stock have an average target of 44.5, with a low estimate of 25 and a high estimate of 64. The average target predicts an increase of 278.08% from the current stock price of 11.77.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for UroGen Pharma stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 3 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| EF Hutton | EF Hutton | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +112.40% | Nov 6, 2024 |
| EF Hutton | EF Hutton | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +112.40% | Oct 29, 2024 |
| EF Hutton | EF Hutton | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +112.40% | Oct 21, 2024 |
| EF Hutton | EF Hutton | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +112.40% | Oct 16, 2024 |
| Oppenheimer | Oppenheimer | Buy Reiterates $40 | Buy | Reiterates | $40 | +239.85% | Oct 16, 2024 |
Financial Forecast
Revenue This Year
94.65M
from 82.71M
Increased by 14.43%
Revenue Next Year
136.71M
from 94.65M
Increased by 44.44%
EPS This Year
-3.34
from -3.55
EPS Next Year
-2.78
from -3.34
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 99.8M | 159.7M | 411.1M | ||
| Avg | 94.7M | 136.7M | 282.0M | ||
| Low | 89.3M | 111.9M | 215.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 20.6% | 68.7% | 200.7% | ||
| Avg | 14.4% | 44.4% | 106.3% | ||
| Low | 8.0% | 18.2% | 57.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.98 | -1.11 | 2.14 | ||
| Avg | -3.34 | -2.78 | -0.51 | ||
| Low | -3.60 | -4.32 | -1.70 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.